We'll be attending Token2049 this year 🇸🇬 @laceywisdom and @frachtisvc are co-hosting a founder and investor circle breakfast on Tues Oct 6th. If you're raising an early stage round or have friends who are - reach out to attend ☕️ luma.com/qx2pxbdl

Precision Neuroscience has closed an oversubscribed $250M Series D, co-led by @PershingSquare Capital Management, The Ackman Oxman Institute, and a leading life sciences investment fund. Total raised: ~$430M. But the financing is only part of the story. Precision now has completed 100+ procedures across 18 major medical institutions. Building BCI requires more than an interface. It requires clinical infrastructure. Since our last financing @PrecisionNeuro_ has also: - Received @FDA clearance for Layer 7™ - Expanded peer-review clinical research - Partnered with @Medtronic - Expanded U.S. MEMS manufacturing The next phase of BCI will be defined not only by what the technology can do in a laboratory. It will be defined by whether companies can build the clinical, regulatory, and manufacturing infrastructure required to bring it to patients. This funding will support: - Expanded clinical work - Additional FDA review - Commercialization infrastructure Read the full news release here: globenewswire.com/news-relea… @BillAckman @PershingSquare @BCapitalGroup, @ARKInvest, @MubadalaCapital, @MiraeAsset, @Hitachi Ventures. Precision’s brain-computer interface is an investigational device and is not available for sale in the United States.